Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily…
Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in…
LAVAL, QC / ACCESS Newswire / September 5, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company,…
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG) today announced compelling preclinical results for…
The Partnership Brings Together Healthcare and Life Sciences Expertise to Drive Data Enablement Innovation CHICAGO, Sept. 3, 2025 /PRNewswire/ --…
LAKE FOREST, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) announced that…
NEW YORK, Sept. 2, 2025 /PRNewswire/ -- 'A Moment of Xen', the acclaimed Tri-State talk show hosted by celebrated media…
Approvals mark a major milestone and bring the most advanced image quality to date to Swoop® system users in European…
Approvals mark a major milestone and bring the most advanced image quality to date to Swoop® system users in European…
Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded…